Tango Therapeutics Inc (TNGX) Noticias

Form 10-Q - Quarterly report [Sections 13 or 15(d)]

Form 8-K - Current report

Tango Therapeutics Reports Third Quarter 2023 Financial Results and Provides Business Highlights

– Dose escalation ongoing in phase 1/2 trials of lead PRMT5 inhibitors TNG908 and TNG462; additional TNG908...

Tango Therapeutics to Present at the Jefferies London Healthcare Conference

BOSTON, Nov. 07, 2023 (GLOBE NEWSWIRE) -- Tango Therapeutics, Inc. (NASDAQ: TNGX), a clinical-stage...

Form 4 - Statement of changes in beneficial ownership of securities

Form SC 13D/A - General statement of acquisition of beneficial ownership: [Amend]

Tango Therapeutics to Highlight Preclinical Data on Precision Oncology Pipeline at AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics

BOSTON, Sept. 18, 2023 (GLOBE NEWSWIRE) -- Tango Therapeutics, Inc. (NASDAQ: TNGX), a clinical-stage...

Form EFFECT - Notice of Effectiveness

Tango Therapeutics Announces FDA Clearance of Investigational New Drug Application for TNG348, a Novel USP1 Inhibitor for the Treatment of BRCA1/2-mutant and Other HRD+ Cancers

BOSTON, Sept. 06, 2023 (GLOBE NEWSWIRE) -- Tango Therapeutics, Inc. (NASDAQ: TNGX), a clinical-stage...

Tango Therapeutics to Participate in the H.C. Wainwright 25th Annual Global Investment Conference

BOSTON, Sept. 05, 2023 (GLOBE NEWSWIRE) -- Tango Therapeutics, Inc. (NASDAQ: TNGX), a clinical-stage...

Form S-3 - Registration statement under Securities Act of 1933

Form 4 - Statement of changes in beneficial ownership of securities

Form 3 - Initial statement of beneficial ownership of securities

Form 8-K - Current report

Tango Therapeutics Announces Updates to Its Board of Directors

BOSTON, Aug. 29, 2023 (GLOBE NEWSWIRE) -- Tango Therapeutics, Inc. (NASDAQ: TNGX), a clinical-stage...